Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences, Inc. is a medical device company focused on the development of non-surgical weight loss devices for obese or overweight patients. The company offers a range of innovative products, including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation. Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the growing demand for safe and effective options in the market.
ReShape Lifesciences (Nasdaq: RSLS) reported an impressive 20% revenue increase for the year ended December 31, 2021, rising from $11.3 million to $13.6 million. The company improved its financial position by eliminating all debt, including a $3 million liability to Apollo Endosurgery related to the purchase of the Lap-Band. As of year-end, ReShape held $22.8 million in cash and cash equivalents. A webcast to discuss financial results and updates will occur on March 28, 2022.
ReShape Lifesciences (Nasdaq: RSLS) announces its participation in two upcoming investor conferences in March. The first, the Oppenheimer 32nd Annual Virtual Healthcare Conference, runs from March 15-17, with CEO Bart Bandy presenting on March 16 at 2:00 PM ET. The Maxim 2nd Annual Virtual Growth Conference follows on March 28-29, featuring a fireside chat with Mr. Bandy on March 28 at 4:30 PM ET. Live broadcasts and replays will be accessible on the company's website. Management will also hold one-on-one meetings during these events.
ReShape Lifesciences (Nasdaq: RSLS) is set to present its next-generation Lap-Band® Program and reshape
ReShape Lifesciences (Nasdaq: RSLS) has appointed Michael Bordainick as Senior Vice President of Commercial Operations, effective January 13, 2022. Bordainick brings two decades of operational and marketing experience, having previously held key roles at Alcon and Kimberly-Clark. His focus will be on enhancing the company’s commercial programs, including direct-to-consumer marketing initiatives for Lap-Band and reshapecare. This appointment aims to accelerate growth and bolster revenue generation strategies amidst rising global health challenges related to obesity.
ReShape Lifesciences (Nasdaq: RSLS) will present a live company overview at VirtualInvestorConferences.com on December 16, 2021, at 2:00 pm ET. CEO Bart Bandy and CFO Tom Stankovich invite investors to participate and ask questions in real-time. An archived webcast will be available for those unable to attend live. Attendees are encouraged to pre-register and complete an online system check. ReShape Lifesciences focuses on weight loss and metabolic health solutions, including the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System.
ReShape Lifesciences Inc. (NASDAQ:RSLS) announced the success of its national advertising campaign and Virtual Media Tour, achieving key performance indicators and exceeding expectations.
In the first five weeks, scheduled patient consults rose by 520%, indicating strong market response. The Lap-Band, a minimally invasive weight-loss solution, is FDA-approved and widely reimbursed. The campaign aims to address obesity, exacerbated by the Covid pandemic, with engaging patient testimonials to resonate with consumers. Ads will now run on additional platforms, enhancing visibility.
ReShape Lifesciences (RSLS) reported Q3 2021 revenue of $3.7 million, a 2.9% increase year-over-year, with a 29.2% revenue growth for the nine-month period. The company launched a national marketing campaign and expanded its product line with new supplements. However, operating expenses surged to $17.1 million due to significant one-time costs, including $10.7 million in stock-based compensation. G&A expenses reached $12 million, reflecting merger-related costs. Despite these challenges, cash and cash equivalents stood at $29.3 million as of September 30, 2021.
ReShape Lifesciences (NASDAQ:RSLS) will report its third quarter 2021 financial and operational results on November 11, 2021, at 8:30 a.m. ET. A webinar discussing these results will be available at 8:45 a.m. ET on the same day, accessible via the Investor Relations page of the ReShape website.
The company focuses on weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® Program and the investigational ReShape Vest™ System. ReShape also provides a virtual weight-management program and an online wellness marketplace.
ReShape Lifesciences (NASDAQ:RSLS) has launched ReShape Optimize™, a new line of supplements tailored for bariatric surgery and weight loss patients, in collaboration with ProCare Health. This expansion seeks to meet the increasing demand for quality supplementation that addresses nutritional deficiencies. Over 195 million U.S. adults take dietary supplements, and the ReShape Optimize line includes multivitamins, probiotics, calcium, and protein supplements. The products will be available on the ReShape Marketplace™, enhancing the company’s comprehensive offerings in the weight loss sector.
ReShape Lifesciences (NASDAQ:RSLS) will be represented by Thomas Stankovich, Chief Financial Officer, at the 6th Annual Dawson James Small Cap Growth Conference on October 21, 2021. The event will take place at the Wyndham Grand Hotel in Jupiter, Florida, and Stankovich's presentation is slated for 2:25 p.m. ET. He will discuss the company's business operations and value creation in its weight-loss product portfolio. Interested investors can schedule one-on-one meetings through their Dawson James contact or Daniel Kontoh-Boateng at The Ruth Group.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
What is Reshape Lifesciences, Inc. focused on?
What are some of the products offered by Reshape Lifesciences?
What is the goal of Reshape Lifesciences?
How does Reshape Lifesciences contribute to the medical field?
